
    
      This study is a randomized phase II study. Patients are randomized to 1 of 2 treatment arms:
      patients receive adjuvant chemotherapy with gemcitabine-oxaliplatin or gemcitabine-cisplatin.
      Chemotherapy should be started within 8 weeks after complete surgical resection. Patients are
      followed every 3 months for 2 years, every 6 months for 3 years.

      Gemcitabine-Oxaliplatin (GemOx) chemotherapy:

      Gemcitabine (1,250 mg/m2)+Oxaliplatin (85 mg/m2) is given on day 1 and 15 q 4weeks. maximum 4
      cycles.

      Gemcitabine-Cisplatin (GemCis) chemotherapy:

      Gemcitabine (1,250 mg/m2) + Cisplatin (40 mg/m2) is given on day 1 and 15 q 4weeks. maximum 4
      cycles.
    
  